Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New marker could numb skin in minutes, study says

NCT ID NCT07273916

Symptom relief Sponsor: Hexsel Dermatology Clinic Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 2 trial tests a topical anesthetic marker applied to the skin to reduce pain from needle pricks. Twenty adults will have the marker applied to their forearm, and pain will be measured every 10 minutes for 40 minutes compared to untreated skin. The goal is to see how well and how fast it works.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
topical anesthetic marker (lidocaine, tetracaine, Transcutol P, and dye)
What this could lead to
If it works, this could provide a quick, easy-to-use topical anesthetic for minor procedures like injections or blood draws.
What could go wrong
This is a small, early-phase trial with only 20 people, testing pain from light pricks on the forearm—not real medical procedures. The effect may not translate to clinical settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 20 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Mar 2026

An estimate. Start dates often move.

Expected to finish

Jun 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age above 18 years. 2. Willingness and ability to undergo the procedures described in the protocol. 3. Candidates who understand and sign the Informed Consent Form (ICF) upon study entry, prior to any study-related procedures. Exclusion Criteria: 1. Pregnant or breastfeeding on the day of the study. 2. History of sensitivity to topical anesthetics or any component of the anesthetic marker formulation. 3. Symptoms of infection at the application site. 4. Eczema or skin alterations at the application site. 5. Any other active inflammations or infections in the treated areas. 6. Any surgical procedure performed that may have affected the area to be assessed in this study. 7. Severe psychiatric disorders. 8. Any other uncontrolled chronic or serious medical condition which, in the investigator's opinion, may interfere with the interpretation of the clinical study results or place the participant at significant risk. 9. Use of analgesic medications. 10. Vulnerable groups (such as individuals deprived of liberty) as defined in Section 1.61 of the International Conference on Harmonisation (ICH) Good Clinical Practice (GCP) Guidelines. 11. Participation in any other clinical drug or device study and/or participation within 7 days prior to Day 1 of this study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Pain management are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

agnosia Pain

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Pain management

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.